Abstract | BACKGROUND: OBJECTIVE: The aim of this study was to evaluate the efficacy of idebenone administration and define the optimal dosage. METHODS: RESULTS/CONCLUSIONS:
Idebenone is well tolerated in paediatric and adult patients. Most trials demonstrated a positive effect on cardiac hypertrophy. The neurological function is in general not modified in adult patients, but a dose-dependent effect was demonstrated in young Friedreich's ataxia patients. Further double-blinded high-dose trials should evaluate idebenone in Friedreich's ataxia early in the disease course.
|
Authors | Caterina Tonon, Raffaele Lodi |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 9
Issue 13
Pg. 2327-37
(Sep 2008)
ISSN: 1744-7666 [Electronic] England |
PMID | 18710357
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antioxidants
- Ubiquinone
- idebenone
|
Topics |
- Antioxidants
(pharmacology, therapeutic use)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Friedreich Ataxia
(diagnosis, drug therapy, physiopathology)
- Humans
- Magnetic Resonance Angiography
- Ubiquinone
(analogs & derivatives, pharmacology, therapeutic use)
|